key: cord-0897183-s6h4w8ot
authors: Abdel-Qadir, Husam; Austin, Peter C.; Pang, Andrea; Udell, Jacob A.; Geerts, William H.; McNaughton, Candace D.; Jackevicius, Cynthia A.; Kwong, Jeffrey C.; Yeh, Calvin; Cox, Jafn L.; Lee, Douglas S.; Ko, Dennis T.; Atzema, Clare L.
title: The association between anticoagulation and adverse outcomes after a positive SARS-CoV-2 test among older outpatients: A population-based cohort study
date: 2021-12-13
journal: Thromb Res
DOI: 10.1016/j.thromres.2021.12.010
sha: 9a8462f7b6dc511c8b83435dcac13847d4f1748c
doc_id: 897183
cord_uid: s6h4w8ot

INTRODUCTION: Anticoagulation may improve outcomes in patients with COVID-19 when started early in the course of illness. MATERIALS AND METHODS: This was a population-based cohort study using linked administrative datasets of outpatients aged ≥65 years old testing positive for SARS-CoV-2 between January 1 and December 31, 2020 in Ontario, Canada. The key exposure was anticoagulation with warfarin or direct oral anticoagulants before COVID-19 diagnosis. We calculated propensity scores and used matching weights (MWs) to reduce baseline differences between anticoagulated and non-anticoagulated patients. The primary outcome was a composite of death or hospitalization within 60 days of a positive SARS-CoV-2 test. We used the Kaplan-Meier method and cumulative incidence functions to estimate risk of the primary and component outcomes at 60 days. RESULTS: We studied 23,159 outpatients (mean age 78.5 years; 13,474 [58.2%] female), among whom 3200 (13.8%) deaths and 3183 (13.7%) hospitalizations occurred within 60 days of the SARS-CoV-2 test. After application of MWs, the 60-day risk of death or hospitalization was 29.2% (95% CI 27.4%–31.2%) for anticoagulated individuals and 32.1% (95% CI 30.7%–33.5%) without anticoagulation (absolute risk difference [ARD], −2.9%; p = 0.005). Anticoagulation was also associated with a lower risk of death: 18.6% (95% CI 17.0%–20.2%) with anticoagulation and 20.9% (95% CI 19.7%–22.2%) in non-anticoagulated patients (ARD -2.3%; p = 0.005). CONCLUSIONS: Among outpatients aged ≥65 years, oral anticoagulation at the time of a positive SARS-CoV-2 test was associated with a lower risk of a composite of death or hospitalization within 60 days.

The coronavirus disease of 2019 has defied conventional treatments for viral pneumonias and the acute respiratory distress syndrome, prompting intense scrutiny of its underlying pathological processes in order to identify novel therapeutic approaches. Patients with COVID-19 have a high risk of thrombosis, prompting the hypothesis that anticipating and counteracting this risk with therapeutic anticoagulation could improve patient outcomes [1] [2] [3] [4] [5] [6] [7] [8] [9] . Several randomized controlled trials (RCTs) have evaluated a strategy of higher-dose versus prophylactic anticoagulation in patients hospitalized with COVID-19 [10] [11] [12] [13] [14] [15] [16] . These studies have yielded conflicting results with regards to efficacy. The benefit of anticoagulation was more likely observed in patients who were not critically ill at time of randomization [10, 11, 13] , suggesting that early initiation of anticoagulation may be integral to deriving benefit from this therapeutic strategy [17, 18] . Indeed, the predisposition to thrombosis among patients with COVID-19 begins before admission to hospital, and early markers of thrombosis at time of hospitalization are predictive of poor downstream outcomes [19] [20] [21] [22] [23] . The ACTIV-4b RCT studied the impact of antithrombotic therapy in symptomatic but stable outpatients with COVID-19 [24] . In this trial, treatment with aspirin or apixaban did not reduce the risk of major adverse cardiopulmonary outcomes. However, this trial studied a relatively low-risk group, and most events occurred before patients began the intervention they were randomized to. Thus, the ideal window of opportunity for anticoagulation in COVID-19 may precede the period studied by the published RCTs.

Since older age is one of the strongest predictors of adverse outcomes following a diagnosis of COVID-19 [22, [25] [26] [27] , we hypothesized that older patients with COVID-19 are the most likely to benefit from early anticoagulation, i.e., before hospitalization. Accordingly, we conducted a population-based cohort study of outpatients aged ≥65 years to examine the association between anticoagulation at time of testing positive for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the subsequent risk of death or hospitalization. We hypothesized that patients who J o u r n a l P r e -p r o o f Journal Pre-proof were anticoagulated would have a lower risk of death and hospitalization following a positive SARS-CoV-2 test. Secondly, we hypothesized that anticoagulation would have a larger protective effect in men than women, as men generally experience acute cardiovascular events at a younger age than women [28] and have worse outcomes following COVID-19 infection [20, 22, 23] .

Ontario is Canada's most populous province; its residents receive universal coverage for physician services and hospital-based care through the Ontario Health Insurance Plan (OHIP). This facilitates the conduct of population-based cohort studies using administrative health datasets that use unique encoded identifiers and are analyzed at ICES (formerly the Institute for Clinical Evaluative Sciences).

The Canadian Institute for Health Information (CIHI) Discharge Abstract Database records data on hospitalized patients, while the National Ambulatory Care Reporting System collects data on emergency department visits; collection of these data is mandatory for all Ontario hospitals. Outpatient prescription medication coverage is provided for patients aged ≥65 years using the Ontario Drug Benefit (ODB) program [29] . Physician billing claims are recorded in the OHIP physician claims database. Residence in long-term care (LTC) can be identified based on physician billings in the OHIP database and ODB drug dispensation records. The Registered Persons Database maintains vital statistics data, including deaths in and out of hospital. Multiple algorithms have been validated to ascertain medical diagnoses using these databases [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . We also used the Johns Hopkins Adjusted Clinical Groups System, Version 10, to determine collapsed Aggregated Diagnosis Groups based on these datasets [46, 47] .

The Ontario Laboratories Information System contains data on laboratory tests, including polymerase chain reaction (PCR) results for SARS-CoV-2. This was used to identify individuals with a positive J o u r n a l P r e -p r o o f Journal Pre-proof SARS-CoV-2 PCR test in Ontario between January 1 and December 31, 2020. For people with more than one positive test, we retained the first test. Next, we applied the following exclusion criteria: missing or invalid key data (age, sex, OHIP number), Ontario non-residents or OHIP coverage <1 year before the SARS-CoV-2 test (to allow ascertainment of medical history), age <65 years plus 100 days (to allow ascertainment of prescription medication exposure), exposure to low molecular weight heparin (which is used for venous thromboembolism [VTE] prophylaxis and cancer-associated thrombosis), or surgery within 6 weeks before the index date (i.e., increased risk of VTE independent of SARS-CoV-2 infection). We also excluded individuals whose index positive SARS-CoV-2 test was collected on a date when the individual was admitted in hospital (i.e., if the testing date was between the admission and discharge dates from hospital, inclusive). The remaining patients constituted the cohort of outpatients with diagnosed COVID-19, whose index date was that of collection of the qualifying SARS-CoV-2 test.

The primary exposure was anticoagulation with warfarin or direct oral anticoagulant (DOAC: apixaban, rivaroxaban, dabigatran, or edoxaban). Patients were defined as anticoagulated if they were dispensed a prescription for warfarin or DOAC in the 100 days preceding the index date (maximum number of days for prescriptions covered by the ODB is 100) with a sufficient supply to include the index date. Patients who were not dispensed a prescription for anticoagulation within 100 days of the index date were classified as non-anticoagulated. We excluded patients who were dispensed 7 primary outcome was chosen to be a composite of death or hospitalization within 60 days of the index date in order to provide a comprehensive estimate of net clinical benefit in outpatients within the health system. We also studied death and hospitalization separately. Furthermore, we assessed the following secondary outcomes: ICU admission, mechanical ventilation, ischemic stroke, acute myocardial infarction, VTE, pneumonia, bleeding events diagnosed in-hospital (which may or may not have been the most responsible diagnosis), and hemorrhagic stroke (see diagnostic codes in Supplementary Table 1 ).

Baseline characteristics were summarized using the mean (with standard deviation [SD]) for continuous variables and frequencies for categorical variables. Standardized differences were used to assess for potentially meaningful differences between anticoagulated and non-anticoagulated individuals [49] .

We calculated propensity scores (PS) for being anticoagulated at the index date conditional on the baseline characteristics listed in Table 1 (please see at end due to formatting). Using the estimated PS, we calculated matching weights (MWs) for each subject in the cohort [50] [51] [52] . Unlike conventional PS weighting approaches, the use of MWs targets inferences at a population with equipoise about the exposure. Once weights were estimated, baseline characteristics were compared between anticoagulated and non-anticoagulated patients using weighted standardized differences, with values <0.1 considered indicative of good balance [53] . Outcomes were then compared between exposed and unexposed subjects in the weighted sample, after which the absolute risk difference (ARD) and numbers needed to treat or harm (NNT/NNH) associated with anticoagulation at 60 days was calculated.

J o u r n a l P r e -p r o o f

We used the Kaplan-Meier (KM) method to compare differences in risk of the composite of death or hospitalization between treatment group, as well as the risk of death (in separate analyses). The cumulative incidence function (CIF) was used to study the risk of hospitalization and other secondary outcomes, while treating death without hospitalization as a competing risk [54] . Patients were censored if they were event-free at the end of the 60-day follow-up window. Statistical significance of differences between groups was determined using the weighted log rank test for the primary outcome and for all-cause mortality. We used a weighted univariable Fine-Gray model with a robust, sandwichtype estimator to determine statistical significance for the remaining outcomes [53] .

Based on clinical considerations, we decided a priori to perform two subgroup analyses. Since we hypothesized that anticoagulation may be more protective in men as a result of their higher baseline cardiovascular risk, we conducted stratified analyses by sex. We also conducted stratified analyses by LTC residency, as the first wave of COVID-19 in Ontario disproportionately affected long-term care (LTC) residents, who tend to be older and frail, with multiple comorbidities and limited life expectancy. They are more likely to have do-not-resuscitate orders, and they were less likely to be transferred to hospital during the pandemic than previously (which is expected to alter hospitalization outcomes in this group) or receive aggressive treatment for severe COVID-19 [48, [55] [56] [57] . Furthermore, we conducted a post hoc analysis wherein DOACS and warfarin were studied separately. The PS was derived, and MW applied separately for each subgroup of interest (men/women, LTC residents/community-dwelling individuals). Figure 2) . Anticoagulation was not associated with significant differences in the 60-day risk of most secondary outcomes (Supplementary Table 2 Subgroup analyses ( Table 3) showed that anticoagulation was associated with comparable reductions in the risk of mortality (RRD of -10% to -15%) but variable directions of associations with regards to hospitalization, leading to some heterogeneity across subgroups in the composite outcome of death or hospitalization. Anticoagulation was associated with a significant reduction in the risk of the composite outcome in men but not in women, and for community-dwelling individuals but not LTC residents. However, anticoagulation was associated with a significant reduction in mortality among LTC residents. DOACs, but not warfarin, were associated with a significant reduction in the composite outcome. Warfarin was associated with a comparable reduction in the risk of mortality, but warfarin-treated people had higher hospitalization risk relative to non-anticoagulated individuals.

Journal Pre-proof LTC: Long-Term Care. RRD= relative risk difference associated with anticoagulation in given stratum. ARD= Absolute risk difference associated with anticoagulation in given stratum.

This population-based cohort study examined the association of oral anticoagulation at the time of positive SARS-CoV-2 test with death or hospitalization among outpatients aged ≥65 years. As Consistent with our a priori hypothesis, among men 65 years of age outpatient anticoagulation had a protective effect against the composite outcome, with ~3% absolute risk reduction at 60 days. At a population level, this absolute risk reduction is clinically meaningful, albeit with a pvalue (0.047) at the traditional border of statistical significance. In subgroup analyses, anticoagulation was not associated with a significantly lower risk of primary or secondary outcomes in women. Anticoagulation was associated with lower risk of the composite outcome in community-dwelling patients (3.5% absolute risk reduction at 60 days), but not among LTC residents. However, anticoagulation was associated with a 3.2% absolute reduction in the risk of death at 60 days in LTC residents. This difference may reflect practice patterns in Ontario during the pandemic, wherein LTC patients with COVID-19 were typically not transferred to hospital if perceived to be at high risk of death [48] . The ACTIV-4b RCT tested the hypothesis that antithrombotic therapy would improve outcomes in stable, symptomatic outpatients with COVID-19. However, the 657 patients in that trial were at lower risk of adverse outcomes than the ones we studied, with 75% of patients aged ≤ 59

years. Furthermore, patients started anticoagulation at a median of 10 days after symptom onset (7 days to randomization, plus 3 days from randomization to anticoagulation). There were 22

(3.3%) hospitalizations (of which 2 were fatal) after randomization but before treatment initiation, but only 5 hospitalization and no deaths after treatment initiation. Our study complements these RCTs by examining the potential impact of anticoagulation at an earlier stage of COVID-19 in an older outpatient cohort.

Our data suggest that exposure to anticoagulation very early in the course of COVID-19

infection warrants further investigation in the high-risk population of older patients who constituted our study cohort. Our analysis overcomes several limitations of prior small studies. A single-site Italian study of 70 patients with chronic heart disease who were diagnosed with COVID-19 and interstitial pneumonia reported that DOAC use at time of COVID-19 diagnosis was associated with lower mortality [59] . Another case-control study reported no significant differences in mortality when comparing 31 anticoagulated patients with 62 non-anticoagulated patients [60] . These two studies could only adjust their analyses for age and sex, given their small Since the sample size and number of events in our study is far larger than all 3 studies combined, we were better powered to detect a potential impact of anticoagulation. We also included a larger number of potential confounders in our PS model and studied a broader range of outcomes.

Importantly, we studied a higher-risk patient population where the risk-benefit balance is more likely to favour initiation of outpatient anticoagulation. We identified one other population-based study [62] , which assessed the association of DOAC use with severe COVID-19 between February and May 2020 using all adults aged 45-84 years in Sweden (rather than restricting the study sample to individuals diagnosed with COVID-19). Since there were <25,000 COVID-19

diagnoses before May 2020 [63] in a population of >10,000,000, this study design cannot be used to make conclusions about the efficacy of OAC use in patients diagnosed with COVID-19. It is also important to highlight that this study did not focus on older patients are at highest risk for severe COVID-19 [22, [25] [26] [27] .

A limitation of our study is its observational design, meaning that we cannot preclude residual confounding A limitation of our study is its observational design, meaning that we cannot preclude residual confounding. If anticoagulation was more readily offered to healthier eligible J o u r n a l P r e -p r o o f Journal Pre-proof patients and avoided in eligible patients at poor health, this treatment bias may have led to better outcomes in anticoagulated patients. Our reliance on administrative datasets means that we cannot report on some variables of clinical relevance (e.g., oxygen use out of hospital or longterm disability). We cannot account for "cross-over" due to initiation, interruption, or nonadherence to anticoagulation after testing positive for SARS-CoV-2; this would potentially bias our results towards the null hypothesis. The ODB program eligibility criteria meant that we could not study the impact of anticoagulation in patients aged <65 years; however, these patients are at lower risk for severe COVID-19, so are unlikely to be considered for anticoagulation before hospitalization if diagnosed with COVID-19. We defined our exposure based on anticoagulation with warfarin or DOAC; though we accounted for prescription antiplatelet use in the PS, we could not determine exposure to aspirin. This limited our ability to assess the impact of antiplatelet use and biases our results towards the null hypothesis (i.e., we would be underestimating the effect of anticoagulation). Finally, our study was conducted before widespread COVID-19 vaccination, so our results do not apply to vaccinated patients.

In this population-based observational study of outpatients diagnosed with COVID-19 aged ≥65 years, oral anticoagulation at the time of a positive SARS-CoV-2 PCR test was associated with a lower risk of death or hospitalization. These results lend support to the hypothesis that initiating oral anticoagulation for high-risk outpatients at the time of a positive SARS-CoV-2 PCR test may yield benefit. However, this observational study does not establish causation; and there was a higher bleeding risk (including haemorrhagic stroke) in anticoagulated patients. Thus, our findings should not prompt the initiation of anticoagulation in patients with COVID-19 who do not have another indication for anticoagulation. Rather, the main implication of our analysis is

Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19

Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience

The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

Anticoagulation in Hospitalized Patients with Covid-19

COVID-19 and its implications for thrombosis and anticoagulation

Coronaviruses and the cardiovascular system: acute and long-term implications

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial

Therapeutic anticoagulation with heparin in critically ill patients with Covid-19

Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated Ddimer concentration (ACTION): an open-label, multicentre, randomised

Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients

Anticoagulation Before Hospitalization Is a Potential Protective Factor for COVID-19: Insight From a French Multicenter Cohort Study

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of Coronavirus Disease 2019 in China

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial

Risk factors associated with mortality among patients with COVID-19 in intensive care units in

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the

Predicting COVID-19 mortality with electronic medical records

Sex/Gender Differences in Cardiovascular Disease Prevention

Coding accuracy of administrative drug claims in the Ontario Drug Benefit database

Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research

ICD-10 adaptations of the Ontario acute myocardial infarction mortality prediction rules performed as well as the original versions

Validation of physician billing and hospitalization data to identify patients with ischemic heart disease using data from the Electronic Medical Record Administrative data Linked Database (EMRALD)

Identifying diabetes cases from administrative data: a population-based validation study

Validity of administrative data for identifying patients who have had a stroke or transient ischemic attack using EMRALD as a reference standard

Identifying Patients With Atrial Fibrillation in Administrative Data

Accuracy of administrative databases in identifying patients with hypertension

Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study

Rates of hemorrhage during warfarin therapy for atrial fibrillation

Identification of Physician-Diagnosed Alzheimer's Disease and Related Dementias in Population-Based Administrative Data: A Validation Study Using Family Physicians' Electronic Medical Records

Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: a validation study

Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study

Accuracy of Administrative Data for the Coding of Acute Stroke and TIAs

The validity of ICD codes coupled with imaging procedure codes for identifying acute venous thromboembolism using administrative data

Administrative data accurately identified intensive care unit admissions in Ontario

Mechanical ventilation in Ontario, 1992-2000: Incidence, survival, and hospital bed utilization of noncardiac surgery adult patients*

Using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a general adult population cohort in Ontario

The Johns Hopkins ACG Case-Mix System, Documentation & Application Manual

COVID-19-related deaths in long-term care: The moral failure to care and prepare

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners

A weighting analogue to pair matching in propensity score analysis

Matching weights to simultaneously compare three treatment groups: comparison to three-way matching

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

Introduction to the Analysis of Survival Data in the Presence of Competing Risks

Coronavirus disease 2019 in geriatrics and long-term care: the ABCDs of COVID-19

Risk factors associated with mortality among residents with coronavirus disease 2019 (COVID-19) in longterm care facilities in Ontario

For-profit long-term care homes and the risk of COVID-19 outbreaks and resident deaths

Therapeutic anticoagulation in critically ill patients with COVID-19-preliminary report

Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era

COVID-19 mortality in patients on anticoagulants and antiplatelet agents

Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study

Direct oral anticoagulant use and risk of severe COVID-19

Coronavirus tracked: see how your country compares

J o u r n a l P r e -p r o o f Journal Pre-proof